Clinical Trials Browser

Phase 2 × Gallbladder Neoplasms × Bevacizumab × Clear all

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05757336 2023-03-07

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Phase 2 Recruiting

Gastrointestinal

Gallbladder Neoplasms

NCT01007552 2017-03-29

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Phase 2 Completed

50 enrolled 12 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT00356889 2014-05-28

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Phase 2 Completed

56 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms

NCT00350753 2009-07-15

Avastin and Tarceva for Upper Gastrointestinal Cancers

Phase 2 Completed

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma